NCT04227028View on ClinicalTrials.gov

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

April 21, 2026

Study Completion Date

April 21, 2026

Conditions
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Brigatinib

Given PO

Trial Locations (6)

17033

Penn State Cancer Institute, Hershey

53792

University of Wisconsin Hospital and Clinics, Madison

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

80045

University of Colorado Cancer Center, Aurora

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER